Regulus Therapeutics (NASDAQ:RGLS)

CAPS Rating: 2 out of 5

Results 1 - 4 of 4

Recs

0
Member Avatar pchop12316 (55.53) Submitted: 2/25/2015 8:24:23 PM : Outperform Start Price: $18.77 RGLS Score: -4.57

positive developments currently

Recs

2
Member Avatar zzlangerhans (99.80) Submitted: 2/3/2015 1:19:42 AM : Outperform Start Price: $17.78 RGLS Score: -5.55

I could spend about six hours analyzing the prospects of RG-101 in the hepatitis C market and then correlating this with Regulus's current market cap, but honestly I'm 70% sure I'd end up with a negative opinion. The reason I own 550 shares of Regulus with cost basis 15.56 is that on October 7 of last year I was on a month-long road trip in Europe with my family when Portefeuille requested that I buy 1500 shares which I executed at 6.73. Two weeks later the company reported viral load reduction data from a phase I trial of RG-101 that caused the stock to rise more than 100%. Our current gains stand at $13000, most of which has been realized in completed sales. Between the Regulus play and another winning bet he suggested while I was completely oblivious to the market, the entire trip was paid for. At the time, I completely forgot to enter a CAPS outperform on Regulus which is why I'm not currently sitting on a 150 point gain there. I'm remedying that oversight now. What will happen when Regulus reports viral load reduction data from a higher dose cohort of RG-101 sometime in the next ten days? I'm really not sure, but I'd have to be a complete idiot not to go with Portefeuille's instructions this time round.

Recs

0
Member Avatar usubanas (99.72) Submitted: 10/23/2014 1:22:41 PM : Underperform Start Price: $14.01 RGLS Score: -19.52

HCV results not that great to justify a 600M mc.

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/22/2013 4:56:09 PM : Underperform Start Price: $9.51 RGLS Score: -61.13

Short. Biotech. High P/S ratio.

Results 1 - 4 of 4

Featured Broker Partners


Advertisement